Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells.

Research output: Contribution to journalJournal articleResearchpeer-review

  1. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. TAM Receptor Inhibition-Implications for Cancer and the Immune System

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
Original languageUndefined/Unknown
JournalJournal for ImmunoTherapy of Cancer
Volume3
Issue numberIssue Suppl 2
ISSN2051-1426
Publication statusPublished - 2015

ID: 65951003